Why the study?
Does captopril improve sodium excretion in clinically stable, hypercapneic patients with advanced chronic obstructive pulmonary disease?
Does captopril improve sodium excretion in clinically stable, hypercapneic patients with advanced chronic obstructive pulmonary disease?
In patients with advanced COPD, ACE inhibition with captopril acutely increases sodium diuresis and alters the osmotic regulation of vasopressin.
May enhance natriuresis in advanced COPD; hypothesis-generating and leaves open effects on volume status or outcomes.
Ten clinically stable, hypercapneic patients with advanced chronic obstructive pulmonary disease were studied to assess the effect of angiotensin-converting enzyme blockade on their inability to excrete a sodium load. Renal, hormonal, and cardiovascular responses to sodium loading were determined during two 5.5-h studies: control day, placebo; and experimental day, captopril. At baseline, compared with control subjects, patients displayed a decrease in urinary sodium associated with low effective renal plasma flow and high plasma level of aldosterone. Captopril, given before sodium loading, produced a significant increase in urinary sodium without increasing effective renal plasma flow and without suppressing plasma aldosterone more than sodium loading alone. Thus, the mechanism by which angiotensin-converting enzyme inhibition induces an acute sodium diuresis in these patients remains to be elucidated. The blockade of angiotensin with captopril also affected the osmotic regulation of vasopressin: for a given increase in plasma osmolality, the increase in plasma vasopressin was subnormal, a finding consistent with the hypothesis that angiotensin II contributes to the regulation of vasopressin secretion.
No takes yet. Share an insight, caveat, or question.
Farber et al. (1987) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: